120 related articles for article (PubMed ID: 38662362)
1. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Serio B; Grimaldi F; Ammirati L; Annunziata M; De Santis G; Perrotta A; De Novellis D; Giudice V; Morini D; Storti G; Califano C; Risitano AM; Pane F; Selleri C
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2044. PubMed ID: 38662362
[TBL] [Abstract][Full Text] [Related]
2. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
3. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Prebet T; Etienne A; Devillier R; Romeo E; Charbonnier A; D'incan E; Esterni B; Arnoulet C; Blaise D; Vey N
Cancer; 2011 Mar; 117(5):974-81. PubMed ID: 20957721
[TBL] [Abstract][Full Text] [Related]
4. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
O'Hear C; Inaba H; Pounds S; Shi L; Dahl G; Bowman WP; Taub JW; Pui CH; Ribeiro RC; Coustan-Smith E; Campana D; Rubnitz JE
Cancer; 2013 Nov; 119(22):4036-43. PubMed ID: 24006085
[TBL] [Abstract][Full Text] [Related]
6. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
[TBL] [Abstract][Full Text] [Related]
8. Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Candoni A; Papayannidis C; Martinelli G; Simeone E; Gottardi M; Iacobucci I; Gherlinzoni F; Visani G; Baccarani M; Fanin R
Am J Hematol; 2018 May; 93(5):655-663. PubMed ID: 29396857
[TBL] [Abstract][Full Text] [Related]
9. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
[TBL] [Abstract][Full Text] [Related]
10. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
[TBL] [Abstract][Full Text] [Related]
11. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
[TBL] [Abstract][Full Text] [Related]
12. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
Amadori S; Suciu S; Stasi R; Salih HR; Selleslag D; Muus P; De Fabritiis P; Venditti A; Ho AD; Lübbert M; Thomas X; Latagliata R; Halkes CJ; Falzetti F; Magro D; Guimaraes JE; Berneman Z; Specchia G; Karrasch M; Fazi P; Vignetti M; Willemze R; de Witte T; Marie JP
J Clin Oncol; 2013 Dec; 31(35):4424-30. PubMed ID: 24127442
[TBL] [Abstract][Full Text] [Related]
13. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
14. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
Bouvier A; Hamel JF; Delaunay J; Delabesse E; Dumas PY; Ledoux MP; Peterlin P; Luquet I; Roth Guepin G; Bulabois CE; Gallego Hernanz MP; Guillerm G; Guieze R; Hicheri Y; Simand C; Himberlin C; Hunault-Berger M; Bernard M; Jourdan E; Caillot D; Dorvaux V; Tavernier E; Daguindau E; Banos A; Ojeda-Uribe M; Gyan E; Alexis M; Marolleau JP; Turlure P; Bouscary D; Humbrecht C; Zerazhi H; Béné MC; Pigneux A; Carre M; Ifrah N; Blanchet O; Vey N; Récher C; Cornillet-Lefèbvre P;
Eur J Haematol; 2021 Jul; 107(1):111-121. PubMed ID: 33765335
[TBL] [Abstract][Full Text] [Related]
15. Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study.
Wang L; Zhao N; Zhou L; Tong J; Xue L; Zhang L; Han Y; Wang X; Geng L; Tang B; Liu H; Zhu W; Cai X; Liu X; Zhu X; Sun Z; Zheng C
Clin Interv Aging; 2022; 17():55-64. PubMed ID: 35082491
[TBL] [Abstract][Full Text] [Related]
16. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
[TBL] [Abstract][Full Text] [Related]
17. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
[TBL] [Abstract][Full Text] [Related]
18. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
Fianchi L; Pagano L; Leoni F; Storti S; Voso MT; Valentini CG; Rutella S; Scardocci A; Caira M; Gianfaldoni G; Leone G
Ann Oncol; 2008 Jan; 19(1):128-34. PubMed ID: 17906298
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adding gemtuzumab ozogamicin to conventional chemotherapy for adult acute myeloid leukemia: a systematic review and meta-analysis.
Guo Y; Deng L; Qiao Y; Liu B
Hematology; 2022 Dec; 27(1):53-64. PubMed ID: 34957930
[No Abstract] [Full Text] [Related]
[Next] [New Search]